CSRxP: House Passage of Bipartisan CREATES Act a Pivotal Moment for Patients

Applauds Lawmakers for Advancing Market-Based Solutions to Lower Drug Prices After Years of Opposition from Big Pharma

For Immediate Release
Contact: Jon Conradi
860-235-3884
[email protected]

Washington, D.C. – The Campaign for Sustainable Rx Pricing (CSRxP) today released a statement praising lawmakers in the U.S. House of Representatives for passing a pair of bipartisan drug pricing bills, the CREATES Act and the Protecting Consumer Access to Generic Drugs Act of 2019:

“We applaud lawmakers in Congress for passing these vital, market-based and bipartisan solutions to hold Big Pharma accountable and lower the price of prescription drugs for American patients,” said CSRxP executive director Lauren Aronson. “The House’s passage of the CREATES Act in particular represents a pivotal moment for American patients. In previous Congresses, steadfast opposition from Big Pharma caused repeated delay for CREATES and other key measures. Lawmakers on both sides of the aisle should be commended for remaining undeterred by previous setbacks and for their dedication to seeing this critical measure passed.”

“We encourage leaders in the Senate to swiftly pass the CREATES Act so it can move quickly to the president’s desk and begin providing relief for millions of Americans struggling with out-of-control prescription drug prices,” Aronson continued. “We urge leaders in the House to capitalize on this momentum by continuing to consider and advance additional bipartisan, market-based solutions to lower prescription drug prices.”

“There is much more work to be done that will require the kind of bipartisan cooperation that marked the advancement of CREATES through the Committee process,” Aronson added. “We encourage leaders, in both parties and in both chambers, to continue to advance market-based solutions to lower the price of prescription drugs in that spirit of bipartisan cooperation to give these measures the greatest possibility of becoming law.”

###

Sign-up for updates

  • This field is for validation purposes and should be left unchanged.